82 related articles for article (PubMed ID: 35728187)
1. Insulin pump special eligibility criteria in New Zealand: a survey of prescriber opinion and practice.
Groves M; Styles S; de Bock M
N Z Med J; 2022 Apr; 135():82-88. PubMed ID: 35728187
[TBL] [Abstract][Full Text] [Related]
2. Youth and non-European ethnicity are associated with increased loss of publicly funded insulin pump access in New Zealand people with type 1 diabetes.
Hennessy LD; De Lange M; Wiltshire EJ; Jefferies C; Wheeler BJ
Diabet Med; 2021 Jan; 38(1):e14450. PubMed ID: 33131079
[TBL] [Abstract][Full Text] [Related]
3. Experiences of Adults Using Continuous Subcutaneous Insulin Infusion: A Qualitative Study.
Mesbah NI; Taha NA; Rahme ZN; Sukkar FF; Omar DM
Med Princ Pract; 2020; 29(3):255-261. PubMed ID: 31557759
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
Potti LG; Haines ST
J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
[TBL] [Abstract][Full Text] [Related]
5. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
Rubin RR; Peyrot M
J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
[TBL] [Abstract][Full Text] [Related]
7. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.
Pickup JC; Yemane N; Brackenridge A; Pender S
Diabetes Technol Ther; 2014 Mar; 16(3):145-9. PubMed ID: 24180294
[TBL] [Abstract][Full Text] [Related]
8. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
9. Young people with type 1 diabetes mellitus: Attitudes, perceptions, and experiences of diabetes management and continuous subcutaneous insulin infusion therapy.
Perry L; James S; Steinbeck K; Dunbabin J; Lowe J
J Eval Clin Pract; 2017 Jun; 23(3):554-561. PubMed ID: 28052468
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study.
Gajewska KA; Biesma R; Bennett K; Sreenan S
Acta Diabetol; 2021 Jan; 58(1):93-105. PubMed ID: 32862261
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and equity of continuous subcutaneous insulin infusions in pediatric type 1 diabetes: A systematic review and meta-analysis of the literature.
Dos Santos TJ; Donado Campos JM; Argente J; Rodríguez-Artalejo F
Diabetes Res Clin Pract; 2021 Feb; 172():108643. PubMed ID: 33359572
[TBL] [Abstract][Full Text] [Related]
12. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R
Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691
[TBL] [Abstract][Full Text] [Related]
13. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
Colquitt JL; Green C; Sidhu MK; Hartwell D; Waugh N
Health Technol Assess; 2004 Oct; 8(43):iii, 1-171. PubMed ID: 15488165
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous insulin infusion versus multiple daily injections for type 1 diabetes.
Ross LJ; Neville KA
J Paediatr Child Health; 2019 Jun; 55(6):718-722. PubMed ID: 31155794
[TBL] [Abstract][Full Text] [Related]
16. Quality of life activities associated with adherence to insulin infusion pump therapy in the treatment of insulin dependent diabetes mellitus.
Wolf FM; Jacober SJ; Wolf LL; Cornell RG; Floyd JC
J Clin Epidemiol; 1989; 42(12):1129-36. PubMed ID: 2585004
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous insulin infusion therapy for Type 1 diabetes mellitus in children.
Mavinkurve M; Quinn A; O'Gorman CS
Ir J Med Sci; 2016 May; 185(2):335-40. PubMed ID: 27083461
[TBL] [Abstract][Full Text] [Related]
18. [Insulin pump therapy in children, adolescents and adults, guidelines (Update 2019)].
Schütz-Fuhrmann I; Stadler M; Zlamal-Fortunat S; Rami-Merhar B; Fröhlich-Reiterer E; Hofer SE; Mader J; Resl M; Bischof M; Kautzky-Willer A; Weitgasser R
Wien Klin Wochenschr; 2019 May; 131(Suppl 1):47-53. PubMed ID: 30980146
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and geographical distribution of insulin pump therapy in the Central Denmark Region and its association with metabolic parameters.
Kampmann U; Madsen LR; Bjerg L; Witte DR; Hasselstrøm K; Østergård T; Alstrup K; Møller MK; Dylmer D; Hansen KW
Diabetes Res Clin Pract; 2018 Jul; 141():148-155. PubMed ID: 29733870
[TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous insulin infusion for managing diabetes: women's health implications.
Hood DG
Nurs Womens Health; 2012; 16(4):308-18. PubMed ID: 22900807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
